Intarcia Therapeutics develops long-acting, implantable drug-delivery therapies built on its proprietary Medici osmotic mini-pump technology. Its lead candidate, ITCA 650, is an investigational implant that delivers exenatide for the chronic treatment of type 2 diabetes; the company submitted its first New Drug Application for this product on November 21, 2016. Looking ahead, Intarcia is partnering with the Bill & Melinda Gates Foundation to adapt the Medici platform for an anti-HIV prophylactic aimed at regions with severe epidemics. The Gates collaboration also includes work on platform enhancements to broaden future therapeutic applications. Financially, the company is in the midst of a multi-tranche Series EE financing designed to fund late-stage clinical, regulatory, and commercialization efforts. Recent capital infusions, coupled with milestone payments such as the $100 million triggered by the ITCA 650 NDA submission, provide significant runway to advance its pipeline and platform.

Total raised

$891M

Funding rounds

6

Latest round

Convertible Note

Latest activity

Apr 2015